Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer.
Mark K DohertyVincent C TamMairéad Geraldine McNamaraRaymond JangDavid HedleyEric ChenNeesha DhaniPatricia TangHao-Wen SimGrainne M O'KaneStephanie DeLucaLisa WangTheresa PedutemJennifer J KnoxPublished in: British journal of cancer (2022)
Adding sequential or continuous selumetinib to CisGem failed to improve efficacy and increased toxicity in patients with advanced BTC.
Keyphrases
- phase ii study
- locally advanced
- open label
- rectal cancer
- squamous cell carcinoma
- papillary thyroid
- placebo controlled
- radiation therapy
- clinical trial
- squamous cell
- study protocol
- double blind
- oxidative stress
- lymph node metastasis
- randomized controlled trial
- pi k akt
- childhood cancer
- cell proliferation
- chemotherapy induced